WallStSmart

Alibaba Group Holding Ltd (BABA)vsBristol-Myers Squibb Company (BMY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alibaba Group Holding Ltd generates 2010% more annual revenue ($1.02T vs $48.19B). BMY leads profitability with a 14.6% profit margin vs 8.9%. BABA appears more attractively valued with a PEG of 1.56. BMY earns a higher WallStSmart Score of 64/100 (C+).

BABA

Hold

49

out of 100

Grade: D+

Growth: 4.0Profit: 6.0Value: 7.3Quality: 5.8
Piotroski: 5/9Altman Z: 2.39

BMY

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 8.5Value: 10.0Quality: 4.5
Piotroski: 6/9Altman Z: 1.42
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BABASignificantly Overvalued (-298.4%)

Margin of Safety

-298.4%

Fair Value

$38.22

Current Price

$129.87

$91.65 premium

UndervaluedFair: $38.22Overvalued
BMYUndervalued (+63.0%)

Margin of Safety

+63.0%

Fair Value

$161.93

Current Price

$58.94

$102.99 discount

UndervaluedFair: $161.93Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BABA3 strengths · Avg: 9.3/10
Market CapQuality
$299.57B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$36.03B10/10

Generating 36.0B in free cash flow

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

BMY5 strengths · Avg: 8.6/10
Return on EquityProfitability
40.4%10/10

Every $100 of equity generates 40 in profit

Market CapQuality
$120.03B9/10

Large-cap with strong market position

P/E RatioValuation
17.0x8/10

Attractively priced relative to earnings

Operating MarginProfitability
28.2%8/10

Strong operational efficiency at 28.2%

Free Cash FlowQuality
$1.60B8/10

Generating 1.6B in free cash flow

Areas to Watch

BABA3 concerns · Avg: 3.3/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

Revenue GrowthGrowth
1.7%4/10

1.7% revenue growth

EPS GrowthGrowth
-70.9%2/10

Earnings declined 70.9%

BMY4 concerns · Avg: 2.8/10
PEG RatioValuation
2.264/10

Expensive relative to growth rate

Revenue GrowthGrowth
1.3%4/10

1.3% revenue growth

Altman Z-ScoreHealth
1.422/10

Distress zone — elevated risk

Debt/EquityHealth
2.551/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : BABA

The strongest argument for BABA centers on Market Cap, Free Cash Flow, Price/Book.

Bull Case : BMY

The strongest argument for BMY centers on Return on Equity, Market Cap, P/E Ratio.

Bear Case : BABA

The primary concerns for BABA are PEG Ratio, Revenue Growth, EPS Growth.

Bear Case : BMY

The primary concerns for BMY are PEG Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.

Key Dynamics to Monitor

BABA carries more volatility with a beta of 0.43 — expect wider price swings.

BABA is growing revenue faster at 1.7% — sustainability is the question.

BABA generates stronger free cash flow (36.0B), providing more financial flexibility.

Monitor INTERNET RETAIL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BMY scores higher overall (64/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alibaba Group Holding Ltd

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Alibaba Group Holding Limited, also known as Alibaba Group and Alibaba.com, is a Chinese multinational technology company specializing in e-commerce, retail, Internet, and technology. Founded on 28 June 1999 in Hangzhou, Zhejiang, the company provides consumer-to-consumer (C2C), business-to-consumer (B2C), and business-to-business (B2B) sales services via web portals, as well as electronic payment services, shopping search engines and cloud computing services. It owns and operates a diverse portfolio of companies around the world in numerous business sectors.

Bristol-Myers Squibb Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

Visit Website →

Want to dig deeper into these stocks?